All In Biotech

Drug Trial Radar · NCT04154488

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

A Phase 1b/2, Open-Label, Multicenter Study of Mavorixafor in Patients With Congenital Neutropenia and Chronic Neutropenia Disorders

Last checked: Nov 19, 2026Latest source record: Aug 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Oct 16, 2021

Primary completion

Aug 27, 2024

Study completion Aug 27, 2024

Sponsor

Lead sponsor
X4 PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Nov 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-part study of mavorixafor in participants diagnosed with chronic neutropenia. The main goal of Part 1 (Phase 1b) is to help researchers learn more about how the investigational medicine, mavorixafor, impacts people living with chronic neutropenia (including congenital, idiopathic, and cyclic). In Part 2 (Phase 2), the safety and tolerability of chronic dosing of mavorixafor will be evaluated in a larger participant population and the impact of 6-month chronic dosing of mavorixafor on participant neutropenia.

Conditions

  • Neutropenia

Interventions

  • MavorixaforDrug

    Mavorixafor capsules will be administered per dose and schedule specified in the arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of MavorixaforTime frame: Baseline through Day 1 and 7 days follow-up
  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Multiple Doses of MavorixaforTime frame: Baseline through Month 6 and 30 days follow-up
  3. Change From Baseline in Absolute Neutrophil Count (ANC) to 8 hours Post-dose On Day 1Time frame: Baseline, 8 hours Post-dose On Day 1
  4. Change From Baseline in ANC to Month 6Time frame: Baseline, Month 6

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • USF Health Department of Pediatrics

    St. Petersburg, Florida

  • University of Iowa Hospital and Clinics

    Iowa City, Iowa

  • University of Michigan

    Ann Arbor, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • University of Texas, Southwestern

    Dallas, Texas

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.